Company
C4X Discovery Holdings PLC
LON:C4XD
C4X Discovery Holdings PLC is a pioneering drug discovery company combining scientific expertise with cutting-edge drug discovery technologies to efficiently deliver world leading medicines. The company has a highly valuable and differentiated approach to drug discovery through its enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. C4X Discovery's commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programmes ready for out-licensing to partners and it has two commercially partnered programmes with one candidate in clinical development.
96 stories
Archive
Small Cap Feast - C4X Discovery Holdings, Greatland Gold, Strategic Minerals, and more...
20 October 2022*A corporate client of Hybridan LLP** Arranged by most recent first*** Alphabetically arrangedDish of the dayJoiners:No joiners today.Leavers:No leavers today.What’s cooking in the IPO kitchen?**Ithaca Energy, a UK independen
C4X Discovery teams up with Chinese drug technology company to identify inflammatory targets
It is working with HitGen Inc, a Shanghai-listed group
Little & large: smaller drug developers are tying up partnerships earlier in the discovery process
Larger drugs companies are looking to snap up new technologies or promising treatments before their rivals and are willing to pay well for the privilege
C4X Discovery raises £5.7mln from institutional investors
The cornerstone investor will be the Polar Capital Biotechnology Fund
C4X Discovery in advanced partnering discussions to out-license third programme
It said it hopes to have the deal for its NRF2 activator programme for inflammatory diseases signed sometime in the second half of this year
C4X Discovery nets €3mln Sanofi milestone payment
The drug developer will also get royalty payments from future sales of the oral interleukin 17A inhibitor under a pre-agreed licensing deal
C4X Discovery in advanced discussions to out-license third drug programme
The update was provided alongside the company's prelims
C4X Discovery Holdings appoints chief scientific officer
Dr Catherine Jane Tralau-Stewart's forte is forging commercial relationships between drug companies and academia
C4X Discovery says portfolio in strong position after “tremendous” full-year progress
“Following the €414mln agreement with Sanofi for our IL-17A oral Inhibitor programme, C4XD is focused on driving forward its portfolio towards future out-licensing opportunities, including NRF-2 where there is significant partnering interes
C4X Discovery appoints biotech industry veteran as new independent director
Dr Mario Polywka will replace Harry Finch in January
C4X Discovery chief Clive Dix given award for contribution to life sciences
“Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive," said C4X Discovery chair Eva-Lott
C4X Discovery science chief to step down
The search for a new chief science officer is already under way, the company said
C4X Discovery focuses on expanding portfolio as it sits on comfortable cash pile
The drug discovery firm said it has enough funding for the foreseeable future
C4X Discovery happy in the pre-clinical world as partner list grows
The drug discovery engine is eyeing future partnerships after securing deals with Sanofi and Indivior
C4X Discovery adds US experience to board with non-exec director appointment
New director Simon Harford will be invaluable as the company continues to grow and expedite major out-licensing deals, said chair Eva-Lotta Allan.
C4X Discovery shifts focus to immuno-inflammatory diseases
Here we take a detailed look at drug discovery company C4X
Archive
Proactive headlines: C4X, Alient Metals, AfriTin Mining…
A look at some of the major headlines from the Proactive newswire
C4X Discovery strikes Sanofi licensing deal worth up to €414mln
The French drugs giant will help develop an oral IL-17 inhibitor to treat inflammatory diseases - tapping into a multi-billion-dollar market
C4X Discovery happy with progress on key drug programmes
“With robust finances now in place, we are strongly positioned to generate commercially attractive data packages for future partners.”
C4X Discovery chief Clive Dix takes over as interim chair of UK Vaccine Taskforce
The UK is the first country to start a mass coronavirus vaccination programme
C4X Discovery raises £15mln to assist with partnership discussions
“Our key programmes continue to demonstrate progress and generate positive data"
C4X Discovery makes significant progress; hails start of Indivior trial, joins coronavirus initiative
“We remain committed to deliver and drive novel small molecule drugs against challenging targets towards clinical development," said CEO Clive Dix
C4X Discovery CEO appointed to UK Vaccine Taskforce
The taskforce has been set up by the UK government’s chief scientific adviser, deputy chief medical officer, business secretary and health secretary to lead efforts to find and manufacture a coronavirus vaccine
C4X Discovery boosts working capital with oversubscribed placing
Funds from the share issue should provide C4X with at least twelve months working capital, assuming it gets its usual tax credits
C4X Discovery hails progress; exited first half in strong financial position
"We continue to progress our portfolio, with our inflammatory programmes generating significant advances,” said chief executive Clive Dix
C4X Discovery confident of its business strategy
"We are making great strides toward our goal of one day becoming the world's most productive drug discovery company," said Eva-Lotta Allan, C4X's chairperson.
C4X Discovery says clinical trials "in sight" for opioid addiction treatment
Indivior was licensed to develop and commercialise C4X's opioid addiction treatment, and it has now selected Altasciences to run early studies into its safety
C4X Discovery unveils plans for £6.5mln fundraising as licensing discussions continue
The drug developer is aiming to raise the funds through a combination of a placing, a subscription and an open offer
C4X Discovery “very confident” of delivering deals in the near future
In a business update it said it is in licensing discussions with potential partners for two of its early-stage drugs
C4X Discovery molecule gets US funding
The award will fund a phase I trial of Orexin-1 along with the toxicology and drug metabolism studies needed to start a phase II assessment
C4X Discovery hires industry heavyweight to lead drug discovery network
The mission of Robin Carr, who has worked with both GlaxoSmithKline and Astex, is to bring together small molecule drug discovery and development experts from across the globe.
Archive
Proactive news snapshot: Metal Tiger, Thor Mining, Berkeley Energia, Galantas Gold …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Creo Medical floats higher after first commercial orders for Speedboat
A look at the day's major movers, including China New Energy, Pressure Technologies, Remote Monitored Systems, Vela, 1pm, Carpetright, RedT, MOD Resources and Metal Tiger
C4X teams up with PhoreMost to look for potential Parkinson’s treatments
By combining their drug discovery and validation platforms, C4X and PhoreMost hope to find drug targets that can potentially treat Parkinson’s sufferers
Archive
Proactive news snapshot: Sirius Minerals, AFC Energy, Location Sciences …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Solid State sparks rally with bullish trading update
A look at some of the biggest risers and fallers in London on Tuesday
C4X Discovery sees significant interest in drug programme
It confirmed it has spoken to "multiple" potential partners for its NRF-2 activator
Archive
FTSE 100 closes in red as China manufacturing data sends chill
The UK's premier share index shed over 22 points at 7,418, while the FTSE 250 shed over 86 points at 19,824
Archive
Impressive first quarter performance needed from oil giant BP after recent share price rally
The Day Ahead also brings updates from the likes of blue-chip lender Standard Chartered, Premier Inn owner Whitbread and pubs group Greene King
Archive
Proactive news snapshot: Strategic Minerals, Kodal Minerals, e-Therapeutics, Ceres Power …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Boku Inc sinks as it buys loss-making company
A look at the day's major movers, including Metals Exploration, Strategic Minerals, Challenger Acquisitions, Gresham Technologies and Countrywide
e-Therapeutics and C4x Discovery team up to find new Parkinson’s treatments
By combining both of their technologies, the companies think they can identify better treatments for Parkinson’s disease
Archive
FTSE 100 has worst day in over two years as Huawei CFO arrest sends shockwaves through markets
Footsie closed down 217 points today to 6,704, with 7,000 now seemingly a distant memory. .
FTSE 100 closes firmly to the good despite EU tensions
Mid-cap cousin FTSE 250 was also higher. It surged over 218 points to close at 18,584.
Archive
Pre-Thanksgiving smorgasbord as plethora of blue-chips report
A relative cornucopia of firms are scheduled to report results on Wednesday ahead of the US holiday, with a sprinkling of and UK and US economic data to taste
Archive
UK investors will have plenty of updates to chew over in the coming week as turkeys are prepared for US Thanksgiving
Aside from the inevitable Brexit drama, the Week Ahead will be dominated by another batch of corporate updates from the likes of Kingfisher, Centrica, easyJet, and Compass Group
Quiz shares strut higher as annual revenues jump
A look at some of the top risers and fallers in London today
Archive
Proactive news snapshot: C4X Discovery, Hurricane Energy, Alba Mineral Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Builders and building materials
Elektron Technology shares rise as subsidiary inks distribution agreement
A look at some of the biggest risers and fallers in London on Thursday
C4X Discovery clinches landmark US$294mln licence deal with Indivior for addiction treatment
It is the first major partnership for the AIM-listed group, which will receive US$10mln up front
Investments and investor services
FTSE 100 closes higher ending an "ugly quarter"; GKN top riser after Melrose succeeds in bid
Turnaround group Melrose received valid acceptances for its offer for GKN representing around 52.43% of the voting rights
Archive
Proactive news snapshot: Synairgen, Iofina, Atlantis Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
C4X Discovery expects “significant progress” in 2018 as it looks for a partner to take its addiction drug through the clinic
“The next year will continue to focus on securing deal revenue from the commercial discussions initiated this year”
Investments and investor services
Scancell Holdings soars after "stunning endorsement" of its ImmunoBody platform
Cancer Research UK was immensely impressed with the company and its technology
C4X Discovery built for growth not a sale
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Archive
Proactive news snapshot: EG Solutions, Richland Resources, Galileo Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
C4X hails progress as it starts to “see the power” of its Taxonomy3 drug discovery platform
C4X is in talks with a “number of potential pharmaceutical partners” that are keen on its drug candidates
Archive
Proactive news round-up: Statpro, Amryt Pharma, Ferrum Crescent...
A snapshot of the stories on the Proactive newswire today
C4X Discovery Holdings says it is on course to become a self-sustaining drugs discovery 'engine'
Its high-value, pre-clinical portfolio has been developed to generate licensing deals
FTSE 100 closes lower as traders mull ECB policy
The FTSE 100 closed at 7,237 as the European Central Bank announced its latest policy decision
Archive
BHP Billiton and banks dominate big week for blue chips
Week ahead: Huge for blue chip announcements with four high street banks, the UK’s two pharma giants, mining titans Anglo and BHP and restaurant to coffee chain Whitbread just a few of those updating.
C4X to raise up to £7mln through a share placing
The company is looking to complete at least one revenue-generating deal on the C4XD portfolio in the next 12 months
Results light up LED group ProPhotonix
Risers and fallers in London at 3,30pm: Prophotonix, Interquest, Surgical Innovations
FTSE shares end lower as sterling marks 8-week low vs dollar on Brexit jitters
FTSE 100 shares closed lower on Tuesday after investors turned edgy over Brexit plans which hit banking and retail shares as well as took sterling to an 8-week low against the US dollar
Archive
Proactive news round-up: Satellite Solutions Worldwide, C4X Discovery, Tissue Regenix …
A glance at some of the stories on the Proactive newswire today
C4X Discovery to focus on early stage licensing deals
From its initial float in 2014, the firm has grown three drug programmes to now eight programmes
Archive
Day Ahead: US jobs data to dominate in absence of corporate news
After US jobs growth of 178,000 in November, market expectations are for the increase in non-farm payrolls to come in at around 160,000 for December.
Investments and investor services
Week Ahead: Next PLC feeling the chill
Happy New Year, Proactive people! That's 2016 done with; Next!
Archive
Proactive news round-up: Breedon Aggregates, C4X Discovery, Advanced Oncotherapy..
A glance at some of the headlines on the Proactive newswire today
C4X raising £5mln to power drug discovery engine
“The completion of this fundraise will allow C4XD to continue on its path to becoming the world's most productive drug discovery engine."
C4X Discovery's bargain buy boosts its drug-finding software
Drug discovery company snaps up software system for "non-material" sum
C4X Discovery acquires new technology
It said it paid a “non-material amount” for the platform, which complements its Conformetrix technology.
C4X Discovery reports drug development progress
Group said its technology had highlighted new areas for potential drug development
C4X Discovery up research spending as programme progresses
C4X has an an ambition to increase the number of pipeline programmes more than threefold by 2019